Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
With funding provided through the Precision Oncology Patient Innovation Award from Bayer, the Canadian Cancer Clinical Trials Network (3CTN) will create the Precision Oncology Map, a uniquely comprehensive, visual representation of all cancer clinical trials active in Canada that have a focus on precision medicine. The goal is to go beyond existing trial registry data to make it easier for cancer patients, their caregivers and the research community to locate suitable clinical trials, particularly precision medicine trials involving specific biomarkers and targeted therapies.
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied. Some of them are extremely rare, with only a few people diagnosed each year.
For 2021/2022 holiday season CCTG will operate with limited coverage on the following dates:
CCTG GI disease site committee says thank you to Dr Breadner for his contribution to the CO.29 study as a new investigator by accruing a patient to a GIDSC trial for the first time, in November 2021.
The San Antonio Breast Cancer Symposium (December 7-10, 2021) is currently underway at the Gonzalez Convention Center in San Antonio, Texas and online.The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
Where and when to see CCTG studies at SABCS 2021: